Abcellera Biologics is trading 10.14% up now at $6.52 after investors focused on more than $112 million in new collaboration upfront payments and imminent ABCL635 Phase 2 data.
- August 5 earnings were mixed: quarterly revenue fell to $4.1 million from $17.1 million, while net loss widened to $55.4 million.
- Management highlighted over $675 million in liquidity and a clinical-stage pipeline supporting longer-term growth.